Evoke Pharma Return on Tangible Equity 2012-2024 | EVOK

Current and historical return on tangible equity values for Evoke Pharma (EVOK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Evoke Pharma Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-09-30 $-0.01B $0.00B -342.86%
2024-06-30 $-0.01B $0.00B -1400.00%
2024-03-31 $-0.01B $0.00B inf%
2023-12-31 $-0.01B $-0.00B 3200.00%
2023-09-30 $-0.01B $-0.00B -533.33%
2023-06-30 $-0.01B $0.00B -246.15%
2023-03-31 $-0.01B $0.00B -168.42%
2022-12-31 $-0.01B $0.00B -168.42%
2022-09-30 $-0.01B $0.01B -168.42%
2022-06-30 $-0.01B $0.01B -177.78%
2022-03-31 $-0.01B $0.00B -188.24%
2021-12-31 $-0.01B $0.00B -156.52%
2021-09-30 $-0.01B $0.01B -225.00%
2021-06-30 $-0.01B $0.01B -400.00%
2021-03-31 $-0.01B $0.01B -1866.67%
2020-12-31 $-0.01B $-0.00B 2600.00%
2020-09-30 $-0.01B $-0.00B -960.00%
2020-06-30 $-0.01B $0.00B -400.00%
2020-03-31 $-0.01B $0.00B -155.56%
2019-12-31 $-0.01B $0.00B -155.56%
2019-09-30 $-0.01B $0.01B -177.78%
2019-06-30 $-0.01B $0.01B -177.78%
2019-03-31 $-0.01B $0.00B -188.24%
2018-12-31 $-0.01B $0.00B -177.78%
2018-09-30 $-0.01B $0.01B -150.00%
2018-06-30 $-0.01B $0.01B -276.92%
2018-03-31 $-0.01B $0.00B -240.00%
2017-12-31 $-0.01B $0.00B -252.63%
2017-09-30 $-0.01B $0.00B -266.67%
2017-06-30 $-0.01B $0.01B -200.00%
2017-03-31 $-0.01B $0.01B -346.67%
2016-12-31 $-0.01B $0.00B -550.00%
2016-09-30 $-0.01B $0.01B -685.71%
2016-06-30 $-0.01B $-0.00B -685.71%
2016-03-31 $-0.01B $0.00B -369.23%
2015-12-31 $-0.01B $0.00B -288.89%
2015-09-30 $-0.01B $0.01B -216.67%
2015-06-30 $-0.01B $0.00B -180.65%
2015-03-31 $-0.02B $0.01B -142.86%
2014-12-31 $-0.01B $0.01B -103.70%
2014-09-30 $-0.01B $0.01B -78.79%
2014-06-30 $-0.01B $0.02B -49.32%
2014-03-31 $-0.01B $0.02B -35.71%
2013-12-31 $-0.00B $0.02B -21.05%
2013-06-30 $0.00B $-0.00B 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.007B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Teligent (TLGT) United States $0.000B 0.00